cGMP compliance for peptide APIs is essential for regulatory approval and patient safety. The global CDMO Service for Peptide APIs market was valued at US$ 3,986 million in 2025 and is anticipated to reach US$ 13,186 million by 2032[reference:137], underscoring the importance of cGMP compliance in this growing market.
cGMP requirements for peptide APIs follow ICH Q7 guidelines, with specific requirements for synthesis, purification, and analytical methods. Key requirements include validated processes, comprehensive documentation, environmental monitoring, and quality control testing. The facility must be designed and operated to prevent contamination and ensure product quality.
Specific considerations for peptide APIs include control of starting materials (including protected amino acids and resins), process control (including coupling efficiency and impurity profiles), and purification (including HPLC conditions and lyophilization). Analytical methods must be validated to demonstrate specificity, accuracy, precision, and robustness.
Documentation is a critical component of cGMP compliance. Batch records must provide a complete record of each manufacturing campaign. Validation reports must demonstrate that processes are capable of consistently producing product meeting specifications. Stability data must support the assigned shelf life. Change control procedures must be followed for any process changes.
Regulatory inspections are a key part of cGMP compliance. Facilities must be prepared for inspections by FDA, EMA, and other regulatory authorities. Inspection readiness includes having current documentation, trained personnel, and robust quality systems. At PeptideHub, we maintain cGMP compliance across our facilities, with the systems and documentation needed to support regulatory submissions and inspections.